Oct 25, 2019
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market
Oct 01, 2019
Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
Sep 30, 2019
Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference
Sep 19, 2019
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
Sep 03, 2019
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 15, 2019
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
Jul 15, 2019
Trovagene Commences Non-Deal Investor Roadshow
May 30, 2019
Trovagene to Host Business Update Conference Call on June 7, 2019
May 23, 2019
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer
May 13, 2019
Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital
Apr 23, 2019
Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
Apr 05, 2019
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
Apr 05, 2019
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
Apr 02, 2019
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
Feb 19, 2019
Trovagene, Inc. Announces Reverse Stock Split
Feb 14, 2019
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference
Jan 23, 2019
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer
Dec 03, 2018
New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML
Nov 15, 2018
Trovagene, Inc. Receives Positive Nasdaq Listing Decision
Nov 13, 2018
Trovagene Announces Launch of New Company Website